EAU 2014 - Poster: A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer: Immune results with a focus on humoral responses

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Emmanuel S. Antonarakis,1 Adam S. Kibel,2 George Adams,3 Lawrence I. Karsh,4 Aymen Elfiky,2 Neal D. Shore,5 Nicholas J. Vogelzang,6 John M. Corman,7 Robert C. Tyler,8 Candice McCoy,8 Todd DeVries,8 Nadeem Sheikh,8 and Charles G. Drake,1, 9 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU 2014 STAND thumb


1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; 2Brigham and Women’s Hospital, Harvard University, Boston, MA; 3Urology Center of Alabama, Homewood, AL; 4The Urology Center of Colorado; 5Carolina Urologic Research Center, Myrtle Beach, SC 6US Oncology Research, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; 7Virginia Mason Medical Center, Seattle, WA; 8Dendreon Corporation, Seattle, WA; 9Brady Urological Institute, Johns Hopkins University, Baltimore, MD

Click HERE to listen to an audio commentary by Robert Tyler, PhD, one of the authors of this study 

Click HERE to read an exclusive report by a UroToday medical writer